79902-31-1

Basic information

• Product Name: 4-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-6-[2-(8-HYDROXY-2,6-DIMETHYL-1,2,6,7,8,8A-HEXAHYDRO NAPHTHALEN-1-YL)-ETHYL]-TETRAHYDRO-PYRAN-2-ONE
• Synonyms: 4-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-6-[2-(8-HYDROXY-2,6-DIMETHYL-1,2,6,7,8,8A-HEXAHYDRO NAPHTHALEN-1-YL)-ETHYL]-TETRAHYDRO-PYRAN-2-ONE;Lovastatin Diol Lactone 4-tert-ButyldiMethylsilyl Ether;(4R,6R)-4-[[(1,1-DiMethylethyl)diMethylsilyl]oxy]-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-diMethyl-1-naphthalenyl]ethyl]tetrahydro-2H-pyran-2-one;2H-Pyran-2-one, 4-[[(1,1-diMethylethyl)diMethylsilyl]oxy]-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-diMethyl-1-naphthalenyl]ethyl]tetrahydro-, (4R,6R)-
• CAS NO: 79902-31-1
• Molecular Formula: C₂₅H₄₂O₄Si
• Molecular Weight: 434.68408
• Product Categories: Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 79902-31-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 540.396°C at 760 mmHg
• Flash Point: 280.622°C
• Appearance: /
• Density: 1.047g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.514
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: Chloroform, Methanol (Sparingly, Heated)
• CAS DataBase Reference: 4-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-6-[2-(8-HYDROXY-2,6-DIMETHYL-1,2,6,7,8,8A-HEXAHYDRO NAPHTHALEN-1-YL)-ETHYL]-TETRAHYDRO-PYRAN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-6-[2-(8-HYDROXY-2,6-DIMETHYL-1,2,6,7,8,8A-HEXAHYDRO NAPHTHALEN-1-YL)-ETHYL]-TETRAHYDRO-PYRAN-2-ONE(79902-31-1)
• EPA Substance Registry System: 4-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-6-[2-(8-HYDROXY-2,6-DIMETHYL-1,2,6,7,8,8A-HEXAHYDRO NAPHTHALEN-1-YL)-ETHYL]-TETRAHYDRO-PYRAN-2-ONE(79902-31-1)

Safety Data

• Hazardous Substances Data: 79902-31-1(Hazardous Substances Data)

Usage

Uses

An intermediate used for synthesis of Simvastatin precursor (H941625).

InChI:InChI=1/C25H42O4Si/c1-16-12-18-9-8-17(2)21(24(18)22(26)13-16)11-10-19-14-20(15-23(27)28-19)29-30(6,7)25(3,4)5/h8-9,12,16-17,19-22,24,26H,10-11,13-15H2,1-7H3/t16-,17-,19+,20+,21-,22-,24-/m0/s1

Upstream product

• 75225-51-3 lovastatin acid 
• 132748-10-8 (3R,5R)-3,5-dihydroxy-7-((1S,2S,6R,8S,8aR)-8-hydroxy-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoic acid 
• 75330-75-5 lovastatin 
• 151006-15-4 (4R,6R)-4-hydroxy-6-(2-((1S,2S,6R,8S,8aR)-8-hydroxy-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)ethyl)tetrahydro-2H-pyran-2-one 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 75-07-0 acetaldehyde 
• 143746-93-4 6(R)-<2-<8-<(trimethylsilyl)oxy>-2(S),6(S)-dimethyl-1,2,6,8a(R)-tetrahydronaphthyl-1(S)>ethyl>-4(R)-<(tert-butyldimethylsilyl)oxy>-3,4,5,6-tetrahydro-2H-pyranone 

Downstream Products

• 1431473-49-2 (1S,3R,7S,8S,8αR)-8-(2-((2R,4R)-4-((tert-butyldimethylchlorosilane)oxy)-6-oxohexahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8α-hexahydronaphthalene-1-yl(4-nitrophenyl)carbonate 
• 1431473-53-8 C₄₂H₆₂N₄O₇Si 
• 1431473-52-7 C₄₁H₆₀N₄O₇Si 
• 1431473-55-0 (4R,6R)-6-[2-((1S,2S,6R,8S,8aR)-8-[((4-{1-[7-(hydroxyamino)-7-oxoheptyl]-1H-1,2,3-triazol-4-yl}benzyl)carbamoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthyl)ethyl]-4-[(tert-butyldimethylsilyl)oxy]-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 1431473-54-9 (4R,6R)-6-[2-((1S,2S,6R,8S,8aR)-8-[((4-{1-[7-(hydroxyamino)-7-oxoheptyl]-1H-1,2,3-triazol-4-yl}phenyl)carbamoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthyl)ethyl]-4-[(tert-butyldimethylsilyl)oxy]-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 1431473-51-6 (4R,6R)-6-[2-((1S,2S,6R,8S,8aR)-8-[((4-ethynylbenzyl)carbamoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthyl)ethyl]-4-[(tert-butyldimethylsilyl)oxy]-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 1431473-50-5 (4R,6R)-6-[2-((1S,2S,6R,8S,8aR)-8-[((4-ethynylphenyl)carbamoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthyl)ethyl]-4-[(tert-butyldimethylsilyl)oxy]-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 1002347-71-8 C₂₅H₃₂⁽²⁾H₆O₅ 
• 1335460-29-1 C₃₁H₄₆⁽²⁾H₆O₅Si 
• 124879-80-7 6(R)-[2-[8(S)-(2-trifluoromethyl-benzoyloxy)-2(S),6(R) dimethyl 1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-tert-butyl-dimethylsilyloxy-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 143747-00-6 6(R)-<2-<8(R)-<(2,2-dimethylbutanoyl)oxy>-2(S),6(S)-dimethyl-7(S)-<1(S)-<(tert-butyldimethylsilyl)oxy>benzyl>-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)>ethyl>-4(R)-<(tert-butyldimethylsilyl)oxy>-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 143746-99-0 6(R)-<2-<8(R)-hydroxy-2(S),6(S)-dimethyl-7(S)-<1(S)-<(tert-butyldimethylsilyl)oxy>benzyl>-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)>ethyl>-4(R)-<(tert-butyldimethylsilyl)oxy>-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 143747-01-7 6(R)-<2-<8(R)-<(2,2-dimethylbutanoyl)oxy>-2(S),6(S)-dimethyl-7(S)-<1(S)-hydroxybenzyl>-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)>ethyl>-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 143746-98-9 6(R)-<2-<8-hydroxy-2(S),6(S)-dimethyl-7(S)-<1(S)-hydroxybenzyl>-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)>ethyl>-4(R)-<(tert-butyldimethylsilyl)oxy>-3,4,5,6-tetrahydro-2H-pyran-2-one 

Relevant articles and documents

A compound targeting ubiquitination degradation HMGCR or a pharmaceutically acceptable salt thereof. Preparation method and application

The invention relates to a compound of targeted ubiquitination degradation HMGCR or a pharmaceutically acceptable salt thereof as well as a preparation method and application thereof. The structure is shown in the general formula (I). The compound or the

Hydroxy methyl glutaryl coenzyme A reductase inhibitors

The invention relates to a compound, in particular to an HMG-GoA reductase inhibitor. The HMG-GoA reductase inhibitor is ester formed by naphthol and Cn polyhydroxyalkanoate or Cn olefine acid of the compound in the formula I, wherein n is an integer from six to fourteen. The compound can be effectively used for treating or preventing dyslipidemia, for example, the compound can effectively treat or prevent hypercholesteremia or mixed type hyperlipidemia.

HYPOCHOLESTEROLEMIC, ANTI-INFLAMMATORY AND ANTIEPILEPTIC NEUROPROTECTIVE COMPOUND

The present invention describes a compound of formula (I) its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. for use in the prevention of: neurodegenerative diseases, cognitive impairment, diseases associated with undesired oxidation, age-associated pathological processes and progeria, cardiovascular diseases such as atherosclerosis, atrial fibrillation, dyslipidemia, hypercholesterolemia, hyperlipidemia, and hypertriglyceridemia, inflammation or inflammatory processes, or epilepsy, epileptic seizures and convulsions.